Skip to Content


Treatment for Idiopathic (Immune) Thrombocytopenic Purpura

Update: Nplate Now FDA Approved - August 22, 2008

Amgen's FDA Nplate Approval Statement Retracted

Amgen's FDA Nplate Approval Statement Retracted

THOUSAND OAKS, Calif., July 14, 2008 — Biotechnology company Amgen Inc. said Business Wire erroneously released a statement from the company Monday, saying the Food and Drug Administration approved its Nplate treatment for a rare type of blood-platelet deficiency condition.

In a separate statement, Business Wire said it prematurely issued the press release.

The drug is in fact still under review by the FDA and the company expects a decision by July 23.

The company said its announcement about the FDA approval, which was released Monday morning, was incorrectly distributed.

Nplate is designed to treat the autoimmune disorder chronic immune thrombocytopenic purpura, in which the number of platelets in a person's blood declines, leading to serious bleeding.

© Copyright 2008 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Posted: July 2008

Related Articles

Nplate (romiplostim) FDA Approval History